Cargando…

Predictive value of baseline metabolic tumor volume for non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis

BACKGROUND: Immune checkpoint inhibitors (ICIs) have emerged as a promising treatment option for advanced non-small-cell lung cancer (NSCLC) patients, highlighting the need for biomarkers to identify responders and predict the outcome of ICIs. The purpose of this study was to evaluate the predictive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Ke, Su, Danqian, Wang, Jianing, Cheng, Zhouen, Chin, Yiqiao, Chen, Luyin, Chan, Chingtin, Zhang, Rongcai, Gao, Tianyu, Ben, Xiaosong, Jing, Chunxia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487526/ https://www.ncbi.nlm.nih.gov/pubmed/36147904 http://dx.doi.org/10.3389/fonc.2022.951557

Ejemplares similares

Deciphering Prognostic Value of TTN and Its Correlation With Immune Infiltration in Lung Adenocarcinoma
por: Chen, Jianing, et al.
Publicado: (2022)

Prognostic Impact of Sarcopenia on Clinical Outcomes in Malignancies Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Li, Shuluan, et al.
Publicado: (2021)

Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy
por: Burke, Aidan M., et al.
Publicado: (2022)

Baseline splenic volume as a biomarker for clinical outcome and circulating lymphocyte count in gastric cancer
por: Zeng, Ziyang, et al.
Publicado: (2023)

Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors
por: Arribas, Lorena, et al.
Publicado: (2021)

Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in (18)F-FDG-PET/CT Imaging for Predicting Pathological Complete Response in Breast Cancers Treated with Preoperative Chemotherapy
por: Higuchi, Tomoko, et al.
Publicado: (2019)

Association of PTPRD/PTPRT Mutation With Better Clinical Outcomes in NSCLC Patients Treated With Immune Checkpoint Blockades
por: Wang, Xiaoyan, et al.
Publicado: (2021)

Deubiquitinating Enzyme: A Potential Secondary Checkpoint of Cancer Immunity
por: Huang, Xing, et al.
Publicado: (2020)

Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis
por: Kiss, Igor, et al.
Publicado: (2022)

The Predictive Value of Tumor Volume and Its Change on Short-Term Outcome for Esophageal Squamous Cell Carcinoma Treated With Radiotherapy or Chemoradiotherapy
por: Liang, Shuai, et al.
Publicado: (2021)

Prognostic values of the gross volume of metastatic lymph nodes in patients with esophageal squamous cell carcinoma treated with definitive concurrent chemoradiotherapy
por: Li, Yang, et al.
Publicado: (2022)

The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

The Prognostic Value of ctDNA and bTMB on Immune Checkpoint Inhibitors in Human Cancer
por: Wei, Jiayan, et al.
Publicado: (2021)

Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer
por: Wang, Wenxian, et al.
Publicado: (2020)

Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition – Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry
por: Placke, Jan-Malte, et al.
Publicado: (2021)

Prognostic value of PET/CT and MR-based baseline radiomics among patients with non-metastatic nasopharyngeal carcinoma
por: Kulanthaivelu, Roshini, et al.
Publicado: (2022)

Prognostic Significance of SUVmax Combined With Lactate Dehydrogenase in Advanced Lung Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Retrospective Study
por: Ke, Linping, et al.
Publicado: (2021)

Identification of the Prognosis Value and Potential Mechanism of Immune Checkpoints in Renal Clear Cell Carcinoma Microenvironment
por: Liao, Guodong, et al.
Publicado: (2021)

Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors
por: Wu, Y. Linda, et al.
Publicado: (2023)

Efficacy of radiomics model based on the concept of gross tumor volume and clinical target volume in predicting occult lymph node metastasis in non-small cell lung cancer
por: Zeng, Chao, et al.
Publicado: (2023)

Prognostic Value of Heterogeneity Index Derived from Baseline (18)F-FDG PET/CT in Mantle Cell Lymphoma
por: Liu, Fei, et al.
Publicado: (2022)

Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab
por: Incorvaia, Lorena, et al.
Publicado: (2023)

The Prognostic Value of Tumor Size, Volume and Tumor Volume Reduction Rate During Concurrent Chemoradiotherapy in Patients With Cervical Cancer
por: Sun, Chang, et al.
Publicado: (2022)

Clinical efficacy of combination therapy of an immune checkpoint inhibitor with taxane plus platinum versus an immune checkpoint inhibitor with fluorouracil plus platinum in the first-line treatment of patients with locally advanced, metastatic, or recurrent esophageal squamous cell carcinoma
por: Li, Ying, et al.
Publicado: (2022)

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
por: Gabryś, H. S., et al.
Publicado: (2022)

Prognostic Significance of Baseline Neutrophil Count and Lactate Dehydrogenase Level in Patients With Esophageal Squamous Cell Cancer Treated With Radiotherapy
por: Luo, He-San, et al.
Publicado: (2020)

Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer
por: Tan, Qiaorui, et al.
Publicado: (2022)

Patterns of Failure in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
por: Chai, Rong, et al.
Publicado: (2021)

Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor
por: Chen, Yang, et al.
Publicado: (2021)

Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade
por: Olsen, T. Anders, et al.
Publicado: (2021)

The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis
por: Wu, Yongfeng, et al.
Publicado: (2019)

The different predictive value of mean platelet volume-to-lymphocyte ratio for postoperative recurrence between non-muscular invasive bladder cancer patients treated with intravesical chemotherapy and intravesical chemohyperthermia
por: Wang, Chengbo, et al.
Publicado: (2023)

Telomere Shortening in Peripheral Leukocytes Is Associated With Poor Survival in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy
por: Rolles, Benjamin, et al.
Publicado: (2021)

Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?
por: Britt, Alec S., et al.
Publicado: (2022)

Use of Baseline (18)F-FDG PET/CT to Identify Initial Sub-Volumes Associated With Local Failure After Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer
por: Lucia, François, et al.
Publicado: (2020)

Prognostic Impact of Baseline Neutrophil-to-Eosinophil Ratio in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Therapy in Second or Later Lines
por: Gil, Lucia, et al.
Publicado: (2022)

Clinical Evaluation of Serum Tumor Markers in Patients With Advanced-Stage Non-Small Cell Lung Cancer Treated With Palliative Chemotherapy in China
por: Abbas, Muhammad, et al.
Publicado: (2020)

Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors
por: Gowen, Michael F., et al.
Publicado: (2018)

Incidence of Skin and Respiratory Immune-Related Adverse Events Correlates With Specific Tumor Types in Patients Treated With Checkpoint Inhibitors
por: Rose, Lynn M., et al.
Publicado: (2021)

DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors
por: Song, Yipeng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h154inr0f2ee2su8vm625j2840